Last reviewed · How we verify

Selg1 — Competitive Intelligence Brief

Selg1 (CRIZANLIZUMAB) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selectin Blocker [EPC]. Area: Metabolic.

marketed Selectin Blocker [EPC] P-selectin Metabolic Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Selg1 (CRIZANLIZUMAB) — Novartis. Selg1 works by binding to P-selectin, preventing it from interacting with its ligands.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Selg1 TARGET CRIZANLIZUMAB Novartis marketed Selectin Blocker [EPC] P-selectin 2019-01-01
Crizanlizumab Injection Crizanlizumab Injection Matthew Neal MD marketed P-selectin inhibitor monoclonal antibody P-selectin
ADAKVEO CRIZANLIZUMAB-TMCA NOVARTIS PHARMS CORP marketed Selectin Blocker [EPC] P-selectin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selectin Blocker [EPC] class)

  1. NOVARTIS PHARMS CORP · 1 drug in this class
  2. Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Selg1 — Competitive Intelligence Brief. https://druglandscape.com/ci/crizanlizumab. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: